The future of personalised risk-stratified breast cancer screening
Will widespread screening for breast cancer based on individual risk mean the end of the one-size-fits-all standard mammogram?
Optimising adjuvant treatment in HR+/HER2-negative early breast cancer
Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment
Sibylle Loibl receives the ESMO Breast Cancer 2022 Award
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
The genomic, immunological and clinical characterisation of breast cancer – a work in progress
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
Immuno-oncology score predicts response to atezolizumab in TNBC
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit
New drugs for an old target: oral SERDs are active in ER+/HER2– breast cancer
Phase I/II trials also show these compounds have more convenient dosing and are well tolerated in both the early and advanced settings
The paradigm shift led by CDK4/6 inhibitors in breast cancer
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
Longer survival benefit with pembrolizumab plus chemotherapy in TNBC
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease